Eurofins Launches EmpowerDX SARS CoV 2 RT PCR Test Back on October 19, 2020

December 22, 2020

Eurofins launched EmpowerDX SARS CoV 2 RT PCR test with an at home sampling option after it received an Emergency Use Authorization (EUA) by the FDA. Demand for the testing kit available at empowerdxlab.com is increasing significantly week on week.

To make patient sampling easier by non-healthcare professionals and especially for testing children, Eurofins validated a sampling method based on gargling with a sterile solution. At-home gargling self-sampling offers the advantage of a simple non-invasive sampling method, allowing patients to be tested without any constraint of medical sampling capacity.

In Germany the EmpowerDx kit for the detection of SARS-CoV-2 is now available for order here and via the GeLaMed app available in the Apple webstore. In Spain the kit working on saliva is available here and here. The kit is delivered to the patient and collected after self-sampling, with results delivered in less than 24 hours.

As this product can significantly expand access to testing, Eurofins will apply for regulatory approval to launch similar tests in the United Kingdom, France, Belgium, Netherlands and Sweden, amongst others.

A version of this product is derived from a test developed by Eurofins Viracor in March 2020 which was ranked by the FDA as the most sensitive out of more than 115 kits evaluated with the FDA reference panel evaluation.

These tests will also detect VUI2020-12/01 virus variants recently reported to be spreading quickly in the UK. Eurofins Genomics also has significant sequencing capacity to identify this or other variants of the virus. (www.eurofins.com/media-centre/press-releases/2020-04-16 )

Given the limited understanding of the prevalence of this new variant in Europe and the consequent potential pandemic acceleration, Eurofins has decided to donate part of its sequencing capacity to national public health authorities who do not have already approved funding to identify VUI2020-12/01 in their positive samples to evaluate local prevalence of this new strain. This knowledge may be useful in deciding on local isolation and travel restrictions.

SourceEurofins
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.
The company announced the launch of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration. Validated for use with Bio-Rad’s Celselect Slides Enumeration Stain Kits, the antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of tumor heterogeneity and disease progression at various stages.
Proteintech advises the new building houses research and development, production, logistics and administration in an area more than three times larger than its previous space.
In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program.
Lindus Health has taken learnings from this experience to build a bespoke "All-in-One Metabolic CRO" offering that combines the expertise of a seasoned full service CRO and internal site/PI expertise with a distinctive technology driven approach on its proprietary Citrus™ platform. This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version